List of Excipients in Branded Drug TROMETHAMINE

Generic Drugs Containing TROMETHAMINE

Company	Ingredient	NDC	Excipient
B Braun Medical Inc	tromethamine	0264-8031	ACETIC ACID
B Braun Medical Inc	tromethamine	0264-8031	WATER
MILLA PHARMACEUTICALS INC	tromethamine	71357-001	ACETIC ACID
MILLA PHARMACEUTICALS INC	tromethamine	71357-001	WATER

What are the Most Frequently-Used Excipients in TROMETHAMINE?

# Of NDCs	Excipient
2	ACETIC ACID
2	WATER

Tromethamine Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: September 5, 2026

Tromethamine, also called trometamol or TRIS, is a versatile pharmaceutical buffer, alkalizing agent and salt-forming counterion. Its standalone excipient position is commercially mature and weakly differentiated, but it creates higher-value opportunities in injectable products, biologics, lyophilized formulations, topical delivery systems and 505(b)(2) products. The strongest intellectual-property positions usually protect a finished drug formulation, a specific tromethamine salt, a manufacturing process or a clinical use rather than tromethamine itself.

What is tromethamine used for in pharmaceutical formulations?

Tromethamine is used primarily to control pH, improve aqueous solubility, form salts with acidic active pharmaceutical ingredients and stabilize drug products.

Attribute	Data
Chemical name	Tromethamine; tris(hydroxymethyl)aminomethane
Common abbreviation	TRIS
Alternative name	Trometamol
CAS number	77-86-1
Molecular formula	C4H11NO3
Molecular weight	121.14 g/mol
Approximate pKa	8.1 at 25°C
Primary formulation role	Buffer, alkalizing agent, salt former
Typical pH operating range	Approximately pH 7 to 9
Common dosage forms	Injectable, ophthalmic, topical, oral liquid, lyophilized and biologic formulations
Regulatory status	Compendial pharmaceutical chemical and approved component in multiple drug products

Tromethamine is particularly useful where a formulation requires a mildly alkaline pH without relying on phosphate or a high concentration of sodium or potassium salts. Its tertiary amino group provides buffering capacity near physiological and mildly alkaline pH values.

Tromethamine also forms salts with acidic drugs. Ketorolac tromethamine and dexketoprofen trometamol are examples of products in which the counterion is part of the drug substance rather than merely an inactive formulation component.

How does tromethamine function as an excipient?

Tromethamine supports four commercial formulation strategies.

pH adjustment and buffering

Tromethamine can maintain formulation pH during manufacturing, storage and administration. The target pH depends on the drug's degradation profile, solubility, route of administration and tissue tolerability.

It is useful where:

• The active ingredient is unstable at neutral pH.
• A weakly acidic drug requires pH elevation.
• Phosphate or citrate creates precipitation or complexation risks.
• The product requires a low sodium load.
• The developer needs a buffer compatible with proteins or nucleic-acid delivery systems.

Buffer capacity is concentration-dependent. A low concentration may have little impact on final pH stability, while a high concentration can increase osmolality, ionic strength and local tolerability risks.

Salt formation

Tromethamine can convert an acidic active ingredient into a more water-soluble tromethamine salt. This may improve:

• Aqueous solubility
• Dissolution rate
• Injectable concentration
• Oral absorption
• Crystallinity and solid-state control
• Manufacturing yield
• Dose uniformity

The salt form can create a distinct drug substance with separate analytical, stability and patent considerations. It does not automatically create a new chemical entity or reset all regulatory exclusivity.

Alkalization

Tromethamine is used to raise pH in products that would otherwise require sodium hydroxide or another strong base. It can produce a more controlled pH adjustment and can reduce the risk of localized pH excursions during manufacture.

Stabilization of complex formulations

Tromethamine can be incorporated into biologic, peptide, vaccine and nucleic-acid formulations when the target pH is compatible with the product. Its value depends on interaction with the active molecule, surfactants, sugars, chelators, amino acids and container materials.

The choice must be supported by real-time and accelerated stability data. Buffer substitution can change aggregation, deamidation, oxidation, particle formation, adsorption and reconstitution behavior.

What formulations are protected by tromethamine patents?

Tromethamine itself is an old, widely available chemical. New patent value generally arises from its use in a defined product context.

Patent strategy	Typical claim scope	Commercial strength
Tromethamine salt	Specific API-tromethamine salt, polymorph, hydrate or solid form	Moderate to strong if the form is difficult to design around
Injectable formulation	API, tromethamine, solvent, pH range and concentration	Moderate if clinical or stability benefits are demonstrated
Biologic formulation	Protein or peptide plus tromethamine and stabilizer system	Moderate, but vulnerable to alternative buffers
Topical formulation	Drug, tromethamine, penetration enhancer, solvent or gel system	Moderate
Ophthalmic formulation	Drug, tromethamine, tonicity agent and preservative system	Moderate
Manufacturing process	Salt formation, crystallization, drying or impurity-control process	Moderate to strong if process-specific
Method of use	Administration of a tromethamine salt for a defined indication or population	Dependent on enforceability and clinical differentiation
Broad excipient claim	Tromethamine as a general buffer or pH adjuster	Weak because of extensive prior art

Patent applicants can seek protection for a narrow pH range, concentration range, buffer ratio, osmolality, impurity profile, particle-size distribution or reconstitution time. Narrow formulation claims are more defensible when linked to a measurable technical effect.

A claim that merely recites "tromethamine as a buffer" is vulnerable to obviousness and enablement challenges. A claim directed to a specific combination that improves stability, reduces aggregation or enables a high-concentration injectable product has greater value.

How does tromethamine affect FDA regulatory strategy?

Tromethamine can be either an inactive ingredient or part of the active drug substance.

As an inactive ingredient

When used as an excipient, the sponsor must establish that the proposed route, dose and concentration are acceptable. The FDA Inactive Ingredient Database provides precedent for excipient use, but database presence does not guarantee acceptance for every route or exposure level. The sponsor must evaluate the proposed formulation against listed route and maximum potency information and provide justification where the use exceeds precedent.[1]

Key development evidence includes:

• Identity and purity
• Residual solvents
• Elemental impurities
• Bioburden and endotoxin controls
• pH and buffer capacity
• Osmolality
• Compatibility with the active ingredient
• Container-closure compatibility
• Extractables and leachables
• Local and systemic tolerability
• Stability under intended storage conditions

As a salt-forming counterion

A tromethamine salt may be treated as the drug substance or active moiety, depending on the product and regulatory history. The sponsor must establish:

• Salt identity and stoichiometry
• Solid-state form
• Water content
• Dissociation behavior
• Equivalence to the reference product
• Impurity profile
• Bioavailability and bioequivalence, where applicable

For an abbreviated new drug application, the applicant must usually match the reference product's active ingredient, dosage form, strength, route and conditions of use. A different salt can create a pharmaceutical-equivalence problem or require a 505(b)(2) pathway rather than a conventional ANDA.

FDA Orange Book status

Tromethamine as a general excipient does not have an independent Orange Book patent listing. The Orange Book identifies approved drug products, therapeutic-equivalence evaluations and certain patents or exclusivity information associated with listed products.[2]

Orange Book analysis must therefore be conducted at the finished-product level. Relevant questions include:

• Is the tromethamine salt the active ingredient listed for the reference product?
• Does the reference product have listed formulation or method-of-use patents?
• Are those patents eligible for Paragraph IV certification?
• Does the product have unexpired regulatory exclusivity?
• Is the proposed generic using the same salt and dosage form?

When does tromethamine lose exclusivity?

Tromethamine has no meaningful standalone pharmaceutical exclusivity. It is a long-established chemical available from multiple suppliers and covered by compendial specifications.

The exclusivity timeline attaches to the product using tromethamine.

Product situation	Primary exclusivity issue
Tromethamine used as an excipient	Product-specific patents and regulatory exclusivity
Tromethamine salt used as API	Drug-substance, formulation and method-of-use patents
New injectable formulation	Composition, stability, device and use patents
Biologic formulation using tromethamine	Biologic exclusivity plus formulation patents
Generic of an existing tromethamine salt	Orange Book patents, Paragraph IV litigation and approval timing
505(b)(2) product	Listed drug patents, regulatory exclusivity and product-specific claims

For small-molecule products, U.S. drug exclusivity can include five-year new chemical entity exclusivity, three-year exclusivity for certain supplements or clinical investigations, and six-month pediatric exclusivity. These periods attach to the qualifying product, not to tromethamine as a chemical excipient.[3]

Patent expiry depends on the individual product's filing dates, patent term adjustment, patent term extension and terminal disclaimers. A reliable expiry date cannot be assigned to "tromethamine" without identifying the drug product and patent family.

What Paragraph IV challenges affect tromethamine products?

Paragraph IV litigation is relevant when an ANDA applicant challenges an Orange Book-listed patent for a product containing a tromethamine salt or tromethamine-based formulation.

A generic applicant may certify that a listed patent is:

• Invalid
• Unenforceable
• Not infringed
• Inapplicable to the proposed product

A Paragraph IV notice can trigger a 30-month stay of FDA approval if the patent holder files an infringement action within the statutory period.[4]

The main litigation risk categories are:

1. Salt identity and equivalence
   The generic sponsor may use the same tromethamine salt but challenge polymorph, hydration or manufacturing claims.

2. Formulation substitution
   A generic may attempt to replace tromethamine with another buffer while maintaining equivalent performance.

3. Method-of-use claims
   A generic may use a "skinny label" that omits patented indications, subject to induced-infringement risk.

4. Process claims
   A patent holder may assert crystallization, drying, impurity-control or particle-size claims.

5. Drug-device combinations
   Injectable or ophthalmic products may include patents covering containers, delivery devices or administration systems.

There is no general Paragraph IV pathway against tromethamine as an excipient supplier. The challenge targets patents listed for a specific approved drug product.

How strong is the patent estate for tromethamine-based products?

The standalone patent estate is weak. The product-specific estate can be moderate or strong.

Stronger patent positions

A sponsor has a stronger position where it can demonstrate:

• A new crystalline tromethamine salt
• Unexpected solubility or stability
• Improved injectable concentration
• Reduced degradation or impurity formation
• Better reconstitution time
• Lower injection-site irritation
• Improved bioavailability
• A manufacturing process that consistently produces a protected form
• Clinical value tied to the formulation

Weaker patent positions

Patent strength is lower where:

• Tromethamine is used only as a conventional pH adjuster.
• The claimed concentration overlaps routine formulation practice.
• Multiple buffers can provide the same result.
• The product has no unexpected stability or pharmacokinetic advantage.
• The claims rely on broad functional language.
• The same formulation appears in prior art or regulatory submissions.

Freedom-to-operate analysis should cover composition, salt form, polymorph, manufacturing, formulation, dosage form, device and method-of-use patents across the United States, Europe, Japan, China and other launch markets.

What commercial opportunities exist for tromethamine suppliers?

The highest-value opportunities are not bulk commodity sales. They are qualified, application-specific products with regulatory documentation and supply assurance.

GMP-grade and low-endotoxin tromethamine

Injectable and biologic developers require stronger controls than conventional industrial TRIS buyers. Suppliers can differentiate through:

• GMP manufacture
• Low endotoxin grades
• Tight bioburden limits
• Metal and aldehyde control
• Lot-to-lot pH performance
• Global regulatory support
• Change-control discipline
• Dual-site manufacturing
• Long-term supply agreements

Ready-to-use buffer systems

A supplier can sell prequalified tromethamine buffer concentrates or sterile liquid systems rather than only raw powder. This can reduce formulation development time and manufacturing complexity.

Commercial products may include:

• Sterile tromethamine buffer
• Concentrated pH-adjustment solutions
• Single-use biologics buffers
• Lyophilized buffer blends
• Custom buffer systems with sugars, surfactants or amino acids

High-concentration injectable products

Many injectable drugs face solubility and volume constraints. Tromethamine salt formation or tromethamine-based pH control can support higher drug concentrations, smaller administration volumes and less frequent dosing.

This opportunity is strongest for acidic small molecules with:

• Poor aqueous solubility
• Existing sodium or potassium salt limitations
• High dose requirements
• Intravenous or subcutaneous administration needs
• A commercial rationale for prefilled syringes or autoinjectors

Biologics and peptide formulations

Tromethamine can be evaluated as an alternative to phosphate, citrate or histidine in protein and peptide products. The commercial opportunity lies in formulation screening, analytical characterization and supply qualification.

Potential targets include:

• Monoclonal antibodies
• Peptide injectables
• Enzyme replacement therapies
• Long-acting proteins
• Vaccines
• Nucleic-acid delivery systems

The key barrier is product-specific compatibility. Buffer choice must not increase aggregation, oxidation, adsorption or immunogenicity risk.

Topical and ophthalmic delivery

Tromethamine can support pH control and solubilization in ophthalmic, nasal and topical products. These products may provide opportunities for 505(b)(2) development when the formulation improves tolerability, delivery or dosing convenience.

Custom tromethamine salts

A contract development and manufacturing organization can offer salt screening, crystallization development and scale-up for acidic APIs. Revenue can come from development fees, manufacturing supply and licensing of formulation IP.

What manufacturing and IP barriers affect market entry?

Tromethamine is relatively easy to source, but pharmaceutical-grade qualification creates barriers.

Manufacturing barriers

Key manufacturing controls include:

• Raw-material traceability
• Control of residual reagents
• Water content
• Nitrogen and carbon-related impurities
• Elemental impurities
• Microbial limits
• Endotoxin, where applicable
• Particle size and flowability
• Packaging moisture protection
• Validated cleaning and cross-contamination controls

For sterile products, the greater challenge is usually the finished formulation rather than the tromethamine raw material. Sterile filtration, container compatibility, pH drift and terminal sterilization can affect product performance.

Intellectual-property barriers

The main barriers are likely to be:

• Existing API salt patents
• Polymorph and hydrate patents
• Formulation patents
• Injectable concentration claims
• Manufacturing process claims
• Device and container patents
• Method-of-use claims
• Trade secrets covering crystallization or impurity control

A supplier selling tromethamine alone generally has limited patent exposure. A supplier developing a proprietary tromethamine salt or finished formulation assumes greater infringement risk but also captures more value.

How does tromethamine compare with other pharmaceutical buffers?

Buffer	Approximate pKa range	Main advantages	Main limitations
Tromethamine	8.1	Mildly alkaline range, low sodium burden, salt formation	Can affect osmolality and protein stability
Phosphate	6.8 to 7.2	Familiar, inexpensive, strong regulatory precedent	Precipitation and metal interaction risks
Citrate	3.1 to 6.4	Broad acidic buffering, common in biologics	Injection-site discomfort and chelation
Histidine	6.0 to 6.5	Common in protein formulations	Narrower pH range and oxidation considerations
Acetate	4.8	Simple and inexpensive	Limited suitability for alkaline products
Tris	8.1	Effective near neutral-to-alkaline pH	Temperature-sensitive pH and biological compatibility considerations

Tromethamine is most commercially attractive when phosphate or citrate creates a specific formulation problem, or when the product requires alkaline pH and low sodium content.

What is the competitive landscape for tromethamine?

The market includes commodity chemical producers, pharmaceutical excipient suppliers, contract manufacturers and drug developers with proprietary tromethamine products.

Competition occurs at three levels:

1. Raw-material supply
   Price, capacity, purity, documentation and supply continuity dominate.

2. Formulation development
   Differentiation comes from stability data, sterile processing, biologic compatibility and regulatory support.

3. Drug-product IP
   Value comes from protected salts, dosage forms, manufacturing methods and clinical outcomes.

Public company disclosures rarely isolate tromethamine revenue. Exposure is usually embedded within broader excipient, buffer, injectable or contract-development businesses. The most attractive targets are suppliers with validated pharmaceutical-grade capacity and developers that control a protected API salt or drug-product formulation.

What generic launch risks exist for tromethamine products?

Generic entry risk depends on the product's regulatory pathway and patent structure.

Product profile	Generic risk
Old tromethamine salt with no listed patents	High
Product protected only by broad formulation claims	Moderate to high
Product with polymorph and process patents	Moderate
Injectable product with complex reconstitution or device requirements	Moderate
Biologic containing tromethamine	Biosimilar and interchangeability risks depend on the biologic, not the excipient
Novel 505(b)(2) formulation	Moderate, depending on listed-drug patents and exclusivity

For biologics, tromethamine does not create a biosimilar barrier by itself. Biosimilar applicants can use a different buffer if they can demonstrate analytical, pharmacokinetic and clinical comparability where required. The reference sponsor's strongest defenses are usually formulation patents, device patents, manufacturing know-how and clinical or regulatory exclusivity.

What are the key commercial conclusions for tromethamine?

Tromethamine is a low-barrier commodity when sold as a general-purpose chemical. It becomes a higher-value pharmaceutical platform when linked to a defined formulation problem, a protected salt form, sterile supply, biologic stability or an improved drug-delivery product.

The best investment and licensing opportunities are:

• High-purity, low-endotoxin GMP supply
• Custom tromethamine salt development
• High-concentration injectable formulations
• Alternative buffer systems for biologics
• Ready-to-use sterile buffer products
• 505(b)(2) reformulations of poorly soluble acidic APIs
• Proprietary crystallization and impurity-control processes
• Global dual-source supply programs

Key Takeaways

• Tromethamine is a buffer, alkalizer and salt-forming counterion with an approximate pKa of 8.1.
• It has no meaningful standalone exclusivity and is widely available as a compendial pharmaceutical chemical.
• Patent value usually resides in the API salt, polymorph, formulation, manufacturing process, dosage form or method of use.
• FDA Orange Book and Paragraph IV issues must be assessed for each finished drug product.
• Tromethamine can support commercial differentiation in injectable, ophthalmic, topical, peptide and biologic formulations.
• Biosimilar risk is product-specific. Tromethamine alone does not block biosimilar entry.
• The strongest supplier opportunity is qualified GMP material combined with formulation, sterile-processing and regulatory services.
• The strongest developer opportunity is a tromethamine salt or formulation with measurable improvements in solubility, stability, tolerability, concentration or administration convenience.

FAQs

Is tromethamine the same as TRIS buffer?

Yes. Tromethamine, trometamol and TRIS refer to the same chemical, although "TRIS buffer" often describes a formulated buffer system rather than the neat pharmaceutical ingredient.

Can tromethamine be used in injectable drugs?

Yes. It is used in injectable products as a buffer, alkalizing agent or salt-forming component. Injectable use requires route-specific evaluation of endotoxin, sterility, osmolality, local tolerability and concentration.

Does tromethamine create a new chemical entity?

Usually not when it is used only as an excipient. A new tromethamine salt can create a distinct drug substance for regulatory and patent analysis, but it does not automatically qualify for new chemical entity exclusivity.

Is tromethamine suitable for monoclonal antibody formulations?

It can be suitable when the target pH and stability profile are compatible. The sponsor must evaluate aggregation, oxidation, deamidation, subvisible particles, viscosity, adsorption and immunogenicity-related attributes.

Can a generic replace tromethamine with another buffer?

Potentially, depending on the reference product, dosage form, active ingredient, equivalence requirements and Orange Book patents. A buffer substitution may require a different regulatory pathway if it changes the drug substance, formulation performance or clinical characteristics.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2014). Guidance for industry: 180-day exclusivity when multiple first applicants are eligible for 180 days. https://www.fda.gov/regulatory-information

4. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Tromethamine monograph. United States Pharmacopeial Convention.

6. U.S. National Library of Medicine. (n.d.). DailyMed: Tromethamine injection labeling. https://dailymed.nlm.nih.gov/dailymed/

7. European Medicines Agency. (2007). Excipients in the label and package leaflet of medicinal products for human use. https://www.ema.europa.eu/

8. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.